Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

D
PII-009
DECIPHERING TYPE 1 DIABETES BY INTEGRATING ARTIFICIAL INTELLIGENCE WITH PANCREATIC WHOLE SLIDE IMAGING

Favorite
PII-188
DEEP DIVE INTO GENERIC DRUG APPLICATIONS TO SEEK DATA-DRIVEN HARMONIZATION OF BIOEQUIVALENCE CRITERIA FOR NARROW THERAPEUTIC INDEX DRUGS.

Favorite
AI-006
DEEP LEARNING PREDICTION OF VANCOMYCIN TIME-CONCENTRATION LEVELS IN NEONATES

Favorite
LB-010
DEEP LEARNING PREDICTION OF VANCOMYCIN TIME-CONCENTRATION LEVELS IN NEONATES

Favorite
PII-199
DESIGN AND MECHANICS OF FIVE MAJOR HUMAN MILK DRUG RESEARCH BIOBANKS: TIME TO CROSS BORDERS AND BARRIERS

Favorite
PII-108
DEVELOPING A PEDIATRIC ORAL SUSPENSION FORMULATION OF ABROCITINIB: A RELATIVE BIOAVAILABILITY AND PALATABILITY ASSESSMENT STUDY IN ADULTS

Favorite
PT-025
DEVELOPMENT AND VERIFICATION OF A NIFEDIPINE CONTROLLED RELEASE PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL IN PREGNANCY

Favorite
LB-011
DEVELOPMENT AND VERIFICATION OF MECHANISTIC PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL FOR ENZALUTAMIDE AND ITS N-DESMETHYL METABOLITE M2 AS INDUCERS OF CYP3A4

Favorite
PII-214
DEVELOPMENT OF A MECHANISTIC CK-PD MODEL TO QUANTITATIVELY CHARACTERIZE A CD19 DIRECTED CAR-T CELL THERAPY PRODUCT DEVELOPED USING RAPID MANUFACTURING

Favorite
PII-042
DEVELOPMENT OF A NOVEL FLUORESCENCE-BASED APPROACH FOR SOLUTE CARRIER-FOCUSED CRISPR/CAS9 KNOCKOUT SCREENING IN BREAST CANCER CELLS

Favorite
PII-166
DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR BALOVAPTAN AND ITS MAJOR METABOLITE TO EVALUATE THEIR CYP3A4-MEDIATED VICTIM DRUG-DRUG INTERACTION (DDI) LIABILITY

Favorite
PII-167
DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR VENLAFAXINE AND O-DESMETHYLVENLAFAXINE: ASSESSING THE IMPACT OF CYP2D6, CYP2C9 AND CYP2C19 GENETIC POLYMORPHISMS

Favorite
PWII-004
DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Favorite
PT-016
DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Favorite
PII-002
DEVELOPMENT OF A TRANSLATION PK-PD MODEL FOR IN VIVO CAR-T CELL THERAPIES USING CAR MRNA LOADED POLYMERIC NANOPARTICLE VECTOR

Favorite
PII-168
DEVELOPMENT OF GRAPHICAL INTERFACE IN R SHINY FOR PBPK MODEL-BASED PREDICTION AND SIMULATION OF DRUG DELIVERY IN THE FEMALE REPRODUCTIVE TRACT

Favorite
LB-012
DEVELOPMENT OF LC-MS/MS METHOD FOR THE SIMULTANEOUS DETERMINATION OF ANTI-NONTUBERCULOUS MYCOBACTERIA PULMONARY DISEASE DRUGS IN HUMAN PLASMA

Favorite
PT-021
DNA METHYLATION PATTERNS OF ARA-C, DAUNORUBICIN, AND ETOPOSIDE PHARMACOKINETIC/PHARMACODYNAMIC GENES ARE ASSOCIATED WITH THE CLINICAL OUTCOMES IN AML.

Favorite
PII-075
DNA METHYLTRANSFERASE INHIBITOR SYNERGIZE WITH IMMUNE CHECK POINT INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER

Favorite
PII-109
DRUG-DRUG INTERACTION (DDI) STUDY OF THE PROTEOLYSIS TARGETING CHIMERA (PROTAC) ANDROGEN RECEPTOR (AR) DEGRADER BAVDEGALUTAMIDE IN COMBINATION WITH THE P-GLYCOPROTEIN (P-GP) SUBSTRATE FEXOFENADINE IN HEALTHY MALE VOLUNTEERS.

Favorite
PII-110
DRUG-DRUG INTERACTION EFFECT OF STEADY STATE LAZERTINIB EXPOSURE ON THE SINGLE-DOSE PHARMACOKINETICS OF MIDAZOLAM, ROSUVASTATIN AND METFORMIN.

Favorite
PII-111
DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF STRONG CYP3A INHIBITION AND P450 INDUCTION ON THE PHARMACOKINETICS OF AFICAMTEN, AND THE EFFECT OF AFICAMTEN ON P-GLYCOPROTEIN, IN HEALTHY PARTICIPANTS.

Favorite
TIP-002
DRUG-GENE-NUTRACEUTICAL INTERACTIONS OF CANNABIDIOL AND TACROLIMUS.

Favorite